The objective of this study was to compare the rate and extent of absorption of pravastatin
sodium from a test formulation of Pravastatin Sodium 80 mg Tablets versus the reference
Pravachol® 80 mg Tablets under fasting conditions.
Based on the results from this study, the two 80 mg pravastatin tablet formulations
demonstrated bioequivalence under the single-dose fasting conditions.
Inclusion Criteria:
- Subjects meeting the following criteria may be included in the study:
- Non-smoking male or female with a minimum age of 18 years.
- Body Mass Index (BMI = weight/height2) greater than or equal to 19 kg/m2 and less than
or equal to 26 kg/m2.
- Availability of subject for the entire study period and willingness to adhere to
protocol requirements, as evidenced by a signed Informed Consent Form.
- Normal findings in the physical examination, 12‑lead ECG and vital signs (blood
pressure between 100‑140/60‑90 mmHg, heart rate between 50-99 beats/min and
temperature between 35. 8°C and 37. 5°C).
- Negative for drugs of abuse, nicotine , alcohol, hepatitis B-surface antigen,
hepatitis C and HIV, and for female subjects, pregnancy (serum ß-CG).
- No clinical laboratory values outside of the acceptable range as defined by BCR,
unless the Principal Investigator decides they are not clinically significant.
- Female subjects who are surgically sterile for at least six months or post-menopausal
for at least one year, or who will avoid pregnancy prior to the study, during the
study and up until one month after the end of the study.
Exclusion Criteria:
- Subjects meeting any of the following criteria will be excluded:
- Known history of hypersensitivity to pravastatin sodium (e. g. Pravachol®, Lipostat®)
and/or related drugs such as simvastatin (Zocor®), atorvastatin (Lipitor™),
cerivastatin (Baycol®) or fluvastatin (Lescol®).
- Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine,
musculoskeletal, neurological, hematological, liver or kidney disease, unless judged
not clinically significant by the Principal Investigator, or medical designate.
- Known history or presence of food allergies, or any condition known to interfere with
the absorption, distribution, metabolism or excretion of drugs.
- Any clinically significant illness during the last four weeks prior to entry into this
study.
- Presence of any significant physical or organ abnormality.
- Any subject with a history of drug abuse.
- Any psychiatric or psychological disease (including depression) unless deemed not
clinically significant by the Principal Investigator, or medical designate.
- Use of any prescription medication within 14 days preceding entry into this study.
- Use of over-the-counter (OTC) medication within seven days preceding entry into this
study (except for spermicidal/barrier contraceptive products).
- Female subjects: use of oral contraceptives or contraceptive implants (such as
Norplant®) within 30 days prior to drug administration or a depot injection of
progestogen drug (e. g. Depo-Provera®) within one year prior to drug administration.
- Female subjects: presence of pregnancy or lactation.
- Any subject who has had blood withdrawals within 56 days preceding this study, taken
during the conduct of any clinical study at a facility other than BCR, or within the
lockout period specified by a previous study conducted at BCR.
- Participation in a clinical trial with an investigational drug within 30 days
preceding this study.
- Any subject who has donated blood within 56 days preceding this study.
- Any subject who has participated as a plasma donor in a plasmapheresis program within
seven days preceding this study.
- Significant or recent history of asthma (after 12 years of age).
- Any subject with a recent (less than one year) history of alcohol abuse.
